Abstract
Tick-borne encephalitis virus (TBEV) is one of the most threatening pathogens which affects the human central nervous system (CNS). TBEV circulates widely in Northern Eurasia. According to ECDC, the number of TBE cases increase annually. There is no specific treatment for the TBEV infection, thus vaccination is the main preventive measure. Despite the existence of several inactivated vaccines currently being licensed, the development of new TBEV vaccines remains a leading priority in countries endemic to this pathogen. Here we report new recombinant virus made by infectious subgenomic amplicon (ISA) approach using TBEV and yellow fever virus vaccine strain (YF17DD-UN) as a genetic backbone. The recombinant virus is capable of effective replication in mammalian cells and induce TBEV-neutralizing antibodies in mice. Unlike the original vector based on the yellow fever vaccine strain, chimeric virus became neuroinvasive in doses of 107−106 PFU and can be used as a model of flavivirus neuroinvasiveness, neurotropism and neurovirulence. These properties of hybrid structures are the main factors limiting their practical use as vaccines platforms.
Funder
Ministry of Health of the Russian Federation
Publisher
Public Library of Science (PLoS)
Reference40 articles.
1. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines;D Ruzek;Antiviral Res,2019
2. Tick-borne encephalitis—Annual Epidemiological Report for 2020. In: European Centre for Disease Prevention and Control [Internet]. 28 Oct 2022 [cited 8 Feb 2023]. Available: https://www.ecdc.europa.eu/en/publications-data/tick-borne-encephalitis-annual-epidemiological-report-2020.
3. The epidemiology of infectious diseases in Europe in 2020 versus 2017–2019 and the rise of tick-borne encephalitis (1995–2020);VA Jenkins;Ticks Tick Borne Dis,2022
4. Clinical development of IMOJEV ®—a recombinant Japanese encephalitis chimeric vaccine (JE-CV);MB Appaiahgari;Expert Opin Biol Ther,2012
5. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children;K Chokephaibulkit;Expert Rev Vaccines,2016